Vaxart, Inc. (VXRT)

0.75 +0.02 (+3.02%) USD  |  OTCM  |  Apr 17, 16:00
More

Vaxart SG&A Expense (Quarterly) : 3.666M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for VXRT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Inovio Pharmaceuticals, Inc. 7.215M
Nuwellis, Inc. 3.213M
Capricor Therapeutics, Inc. 6.025M
Allogene Therapeutics, Inc. 13.77M
Silvergate Capital Corp. --